Microbix Completes Final Closing of Private Placement

/NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE SERVICES./

TORONTO, Aug. 29, 2014 /CNW/ - Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today confirmed that it has closed the second and final tranche of the recently announced private placement offering.

Microbix is pleased to announce that the offering was fully subscribed with the issuance of an aggregate of 5,128,206 units, of which 1,994,183 units were issued in the second tranche. Microbix received total gross proceeds from the offering of $2,000,000. Each unit consists of one common share of Microbix and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at an exercise price of $0.55 for five years. Insiders of the Company participated in the financing by purchasing an aggregate of 1,964,615 units representing over 38% of the offering. The financing was non-brokered.  A total of 121,555 finder's warrants were issued.  Each finder's warrant entitles the holder to purchase one unit at a price of $0.47 for a period of five years.

The securities issued in the private placement are subject to a hold period of four months and one day from the date of issue. The private placement is subject to final approval by the Toronto Stock Exchange.

Vaughn C. Embro-Pantalony, President and CEO of Microbix commented, "I am very pleased the private placement was fully subscribed, and that it received such strong support from insiders. The proceeds from this financing ensure there will be no funding related delays as we continue to advance the growth priorities of our Company."

The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to a U.S. Person absent an exemption from the registration requirements.

The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

About Microbix Biosystems Inc.
Microbix Biosystems Inc. specializes in the research and development of biological solutions, including products for human health applications, namely in the vaccine, therapeutic and diagnostic markets, as well as animal reproductive markets worldwide. The Company manufactures and distributes a wide range of infectious disease antigens to a worldwide customer base. The Company's pipeline of innovative technologies and products includes LumiSort™ semen sexing technology for the livestock industries, Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX®, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange, and headquartered in Mississauga, Ontario.

Disclaimer
This press release may contain forward-looking statements which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with development projects, operations in foreign jurisdictions, risks associated with engineering and construction generally, risks associated with production including control over costs, quality, quantity and timeliness of delivery of products, foreign currency and exchange rate risk, and risks of raising capital on acceptable terms or at all.  These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.

%SEDAR: 00004220E

SOURCE: Microbix Biosystems Inc.

Visit www.microbix.com or contact: Vaughn Embro-Pantalony, President and CEO, [phone] x 350; or Charles Wallace, CFO, [phone] x 255